Skip to content

Effect of Precision Blood Pressure Management on Maternal and Neonatal Outcomes in Pregnant Women with Chronic Hypertension: A Randomized Controlled Trial

Effect of Precision Blood Pressure Management on Maternal and Neonatal Outcomes in Pregnant Women with Chronic Hypertension: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114170
Enrollment
Unknown
Registered
2025-12-08
Start date
2025-12-08
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive Disorders of Pregnancy

Interventions

Control Group:Standard care
Experimental Group:Precision Blood Pressure Management

Sponsors

Guangzhou Women and Children's Medical Center, Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Aged >=18 years; 2.Singleton pregnancy with a gestational age =140 mmHg and/or diastolic blood pressure >=90 mmHg detected before 20 weeks of gestation, without significant exacerbation during pregnancy or presenting as acute severe hypertension; 4.Planning to receive antenatal care and deliver at our hospital, with good adherence and the ability to complete scheduled follow-up assessments; 5.Agrees to participate in the study and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Fetal chromosomal abnormalities and structural abnormalities; 2.Multiple pregnancies; 3.Patients who are allergic to antihypertensive drugs or are prohibited from using such drugs for other reasons; 4.Unable to complete ABPM or USCOM assessments, or refusing medication intervention; 5.Women with poor compliance and cannot have regular pregnancy check-ups; 6.Presence of psychiatric disorders or cognitive impairment that prevents effective communication with the study team.

Design outcomes

Primary

MeasureTime frame
Incidence of preeclampsia;

Secondary

MeasureTime frame
Severe hypertension (systolic BP >160 mmHg and/or diastolic BP =110 mmHg);Eclampsia;HELLP syndrome;liver dysfunction (ALT or AST >70 IU/L), renal dysfunction (creatinine >150 µmol/L), thrombocytopenia (<100×10?/L), stroke, pulmonary edema, placental abruption, and uteroplacental dysfunction ( fetal growth restriction, abnormal umbilical artery blood flow, or intrauterine fetal death).;birth weight, incidence of small for gestational age (SGA), preterm birth rate (gestational age < 37 weeks ), and NICU admission rate.;Total dosage and types of antihypertensive drugs;

Countries

China

Contacts

Public ContactJiang Yanmin

Guangzhou Women and Children's Medical Center, Guangzhou Medical University

13189081153@163.com+86 131 8908 1153

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026